Research map: Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer

Back to the article

Papers in this map

  1. Integrative Clinical Genomics of Advanced Prostate Cancer · Dan R. Robinson · 2015 · 3730 citations · Cited by this paper
  2. Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study · 2026 · Related
  3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer · Christopher J. Sweeney · 2015 · 2922 citations · Cited by this paper
  4. Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe · 2026 · Related
  5. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer · Karim S. Fizazi · 2017 · 2313 citations · Cited by this paper
  6. Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer · 2025 · Related
  7. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 · Howard I. Scher · 2016 · 1672 citations · Cited by this paper
  8. Persistence, progression, and PSA: what exactly does DEAR-EXT compare? · 2026 · Related
  9. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer · Andrew J. Armstrong · 2019 · 1241 citations · Cited by this paper
  10. Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates · 2026 · Related
  11. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial · Karim S. Fizazi · 2019 · 841 citations · Cited by this paper
  12. Prostate biopsy - current discussions and future perspectives · 2026 · Related
  13. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design · Karim S. Fizazi · 2022 · 828 citations · Cited by this paper
  14. Counseling is counseling is counseling is counseling - The evolution of LUTS/BPO care · 2026 · Related
  15. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making · Wassim M. Abida · 2017 · 544 citations · Cited by this paper
  16. Navigating drug–drug interactions with apalutamide · 2026 · Related
  17. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial · Maha Hussain · 2023 · 230 citations · Cited by this paper
  18. Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial · 2026 · Related
  19. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial · Christopher J. Sweeney · 2023 · 205 citations · Cited by this paper
  20. Insights gained from single-cell transcriptomics on the cellular identity and plasticity of prostate epithelial cells · 2026 · Related
  21. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer · Konrad Hermann Stopsack · 2020 · 187 citations · Cited by this paper
  22. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity · Gunther Boysen · 2018 · 147 citations · Cited by this paper
  23. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer · Manish Kohli · 2020 · 142 citations · Cited by this paper
  24. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) · Silke Gillessen · 2024 · 133 citations · Cited by this paper
  25. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol · Gerhardt Attard · 2023 · 116 citations · Cited by this paper
  26. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials · Claire Louise Vale · 2023 · 95 citations · Cited by this paper
  27. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476) · Nicholas David James · 2022 · 80 citations · Cited by this paper
  28. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer · Umang Swami · 2022 · 74 citations · Cited by this paper
  29. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer · Miguel González Vélez · 2021 · 72 citations · Cited by this paper
  30. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate · Gerhardt Attard · 2015 · 56 citations · Cited by this paper
  31. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study · Karim S. Fizazi · 2025 · 45 citations · Cited by this paper
  32. Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis · Junru Chen · 2023 · 37 citations · Cited by this paper
  33. Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial · Clare Gilson · 2020 · 35 citations · Cited by this paper
  34. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial · Bram De Laere · 2024 · 31 citations · Cited by this paper
  35. Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy · Axel S. Merseburger · 2024 · 27 citations · Cited by this paper
  36. Survival in Patients With De Novo Metastatic Prostate Cancer · Martin W. Schoen · 2024 · 26 citations · Cited by this paper
  37. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk · Arun Azad · 2021 · 25 citations · Cited by this paper
  38. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES · Andrew J. Armstrong · 2023 · 24 citations · Cited by this paper
  39. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer · Jacob J. Orme · 2023 · 21 citations · Cited by this paper

Source: OpenAlex (CC0)